First-line, FDA-cleared CBT for insomnia & anxiety

Give patients instant access to guideline-recommended digital treatments with SleepioRx and DaylightRx.

Request Demo

FDA-Cleared

500K+ Patients

Treated & supported

App Store Rating

Vetted & Secure

HIPAA compliant &
HITRUST certified

Reimbursable

by Insurance

Fully digital, first-line, cognitive-behavioral therapy (CBT) for patients

Immediate access to evidence-based care for patients

Get patients instant access to CBT-I, a gold-standard treatment for insomnia disorder and generalized anxiety disorder^1,2

Expanded, reimbursable care options for clinicians

Address high patient demand and long waitlists with reimbursable, FDA-cleared digital mental health treatments

Scalable mental health care for systems & practices

Grow your practice by expanding services and increasing patient volume without overburdening clinicians

Explore Treatments

Read FAQs

DIGITAL TREATMENTS REIMBURSED THROUGH INSURANCE

Sleepio RX

76% of insomnia patients achieve clinical improvement with no serious side effects³

Daylight RX

71% of anxiety patients achieve clinical improvement with no serious side effects⁴

Expand access and close care gaps

Clinical use cases for FDA-cleared treatments

First-line care

SleepioRx + DaylightRx provide first-line recommended treatment for insomnia & anxiety

PCPs, Psychiatrists, Sleep medicine

Waitlist support

SleepioRx + DaylightRx provide support for patients on long waitlists

Therapists, Psychiatrists, Sleep medicine

Therapy reinforcement

SleepioRx + DaylightRx reinforce therapy skills and support practice of CBT between sessions

Therapists, Sleep medicine

Rx combination
or discontinuation

In combo with meds, SleepioRx + DaylightRx improve outcomes or support discontinuation

PCPs, Psychiatrists, Sleep medicine

Comorbid condition
treatment

SleepioRx + DaylightRx reinforce therapy skills and support practice of CBT between sessions

Therapists, Psychiatrists

Maintenance support

Offered ahead of treatment termination, SleepioRx + DaylightRx help maintain CBT skills

Therapists, Psychiatrists, Sleep medicine

Request Demo

BY THE NUMBERS

Evidence for SleepioRx and DaylightRx

Read the Research

50+

Peer-reviewed evidence publications

Completed randomized controlled trials

References in clinical guidelines like the American College of Physicians¹

FAQs

What are SleepioRx and DaylightRx?

SleepioRx¹ and DaylightRx² are FDA-cleared digital treatments for insomnia disorder and generalized anxiety disorder, respectively, delivering guideline-recommended cognitive behavioral therapy (CBT) through video and audio lessons in mobile apps. Designed by sleep and anxiety experts, the treatments help patients understand unhealthy patterns and address the thoughts and behaviors that sustain insomnia and anxiety. CBT techniques delivered in an engaging and interactive format help patients overcome insomnia and anxiety, quickly.
‍

1. SleepioRx is a digital therapeutic intended for the treatment of chronic insomnia/insomnia disorder as an adjunct to usual care in patients aged 18 and older. SleepioRx is a prescription device delivering Cognitive Behavioral Therapy for Insomnia (CBT-I) and can be made available on the order of a licensed healthcare provider. Patients should read the instructions for use for full information.2. DaylightRx is a prescription device delivering Cognitive Behavioral Therapy and can be made available on the order of a licensed healthcare provider. DaylightRx is a digital therapeutic intended to treat generalized anxiety disorder (GAD) by improving a patient's GAD symptoms as an adjunct to usual care in patients aged 22 years and older. Patients should read the instructions for use for full information.

What evidence is there showing that SleepioRx and DaylightRx work?

SleepioRx has been tested to the highest standards of clinical evidence in 26 clinical trials, including 18 randomized controlled trials (RCTs). Across these studies, SleepioRx outperforms rigorous controls, including sham-placebo, usual care, and sleep hygiene, with up to 76% of SleepioRx patients achieving healthy sleep by post-treatment.^1-4 Data suggest that patients continue to experience benefits 1 year or longer after starting SleepioRx.^5,6

DaylightRx has been evaluated across 2 rigorous RCTs and one single-arm trial. DaylightRx has demonstrated superiority compared to an active psychoeducation control, with 71% of DaylightRx participants achieving GAD remission based on clinical interview compared to 35% of control participants,⁷ with consistent results observed on self-reported measures.⁸ Results from these trials demonstrate that benefits conferred by DaylightRx are maintained until at least 6 months.^7
‍

1. Espie et al. (2012). SLEEP, 35(6), 769-781.
2. Tamm et al. (2025). JAMA Network Open, 8(2), e2461502-e2461502.
3. Tarnai et al. (2025). Aging and Mental Health, 1-7
4. Internal RCT data, August 2023.
5. Luik et al. (2020). Journal of Sleep Research, 29(4), e13018.
6. Cheng et al. (2021). SLEEP, 44(4), zsaa258.
7. Internal RCT data, September 2023.
8. Carl et al. (2020). Depression & Anxiety, 37(12), 1168-1178.

How do I order SleepioRx and DaylightRx for my patients?

You can place an order and start distributing SleepioRx or DaylightRx to your qualifying patients in three simple steps:
‍
Step 1: Big Health provides providers with a website for ordering, along with unique access codes. Print and digital referral materials are also available if needed.
Step 2: The provider identifies qualifying patients, explains SleepioRx or DaylightRx, and enters a unique access code and the patient's phone number on the website.Step
3: The patient receives a text message with instructions for accessing, downloading and signing up for SleepioRx or DaylightRx.

Which insurers cover SleepioRx and DaylightRx?

The Centers for Medicare & Medicaid Services (CMS) has finalized three new Digital Mental Health Treatment (DMHT) codes in the Calendar Year (CY) 2025 Medicare Physician Fee Schedule as of January 1, 2025, allowing providers a reimbursement opportunity for prescribing DMHTs like SleepioRx and DaylightRx to Medicare patients. While we are actively engaging other insurance carriers to expand coverage, these DMHT codes are not a guarantee of reimbursement.

What types of providers can authorize use of SleepioRx and DaylightRx and bill for reimbursement?

Licensed providers who are able to offer behavioral therapy or behavioral health care within their scope of practice can order SleepioRx or DaylightRx and bill for the codes.This includes the following practitioners:
‍
- Psychiatrists & other doctors (MDs, DOs)
- Clinical psychologists
- Clinical social workers (LCSWs, LICSWs)
- Advanced practice nurses/Nurse practitioners (NPs)
- Physician assistants (PAs)
- Marriage & family therapists (LMFTs)
- Mental health counselors
‍
Check commercial payer policies for restrictions. The billing practitioner or a colleague should oversee patient care and adjust treatment as needed. They may also supervise non-qualifying practitioners in providing these services.

Ready to offer patients FDA-cleared treatments?

Qaseem A, Kansagara D, Forciea MA, Cooke M, Denberg TD; Clinical Guidelines Committee of the American College of Physicians. Management of Chronic Insomnia Disorder in Adults: A Clinical Practice Guideline From the American College of Physicians. Ann Intern Med. 2016 Jul 19;165(2):125-33. doi: 10.7326/M15-2175. Epub 2016 May 3. PMID: 27136449
DeGeorge KC, Grover M, Streeter GS. Generalized Anxiety Disorder and Panic Disorder in Adults. Am Fam Physician. 2022 Aug;106(2):157-164. PMID: 35977134.
Changes up to these levels have been demonstrated across studies, including:
- Espie, C. A., Kyle, S. D., Williams, C., Ong, J. C., Douglas, N. J., Hames, P., & Brown, J. S. (2012). A randomized, placebo-controlled trial of online cognitive behavioral therapy for chronic insomnia disorder delivered via an automated media-rich web application. SLEEP, 35(6), 769–781.
- Tarnai, Kathryn A; Miller, Christopher B; Magill, Nicholas; Emsley, Richard; Robinson, Will; Kyle, Simon D; McGrath, Emer R; Espie, Colin A; Henry, Alasdair L. (2025). Efficacy of digital cognitive behavioral therapy for treating insomnia in adults aged 65 and older: a secondary analysis using individual participant data from three randomized controlled trials. Aging and Mental Health. pp. 1-7. ISSN 1360-7863.
Carl, J. R., Miller, C. B., Henry, A. L., Davis, M. L., Stott, R., Smits, J. A. J., Emsley, R., Gu, J., Shin, O., Otto, M. W., Craske, M. G., Saunders, K. E. A., Goodwin, G. M., & Espie, C. A. (2020). Efficacy of digital cognitive behavioral therapy for moderate-to-severe symptoms of generalized anxiety disorder: A randomized controlled trial. Depression and anxiety, 37(12), 1168–1178. https://doi.org/10.1002/da.23079

SleepioRx and DaylightRx are prescription digital therapeutics, available by order of a licensed healthcare provider, for use alongside usual care. SleepioRx treats chronic insomnia in adults 18+, and DaylightRx treats generalized anxiety disorder (GAD) in adults 22+. Patients should read the instructions for use for full information. These statements are in no way intended to imply or suggest any claims regarding SleepioRx and DaylightRx beyond its FDA cleared indications and should in no way be considered a guarantee of coverage or reimbursement for any product or service. These statements are intended to provide information to practitioners, they do not seek to maximize payment, and should not be mistaken for official payer guidance.

DOC-3895 Effective June 2025